Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor

Evaluating the combination of brentuximab vedotin with ipilimumab and nivolumab in relapsed/refractory Hodgkin lymphoma.

Evaluating the combination of brentuximab vedotin with ipilimumab and nivolumab in relapsed/refractory Hodgkin lymphoma.

Posted by on Feb 7, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of combination regimens of brentuximab vedotin (BV; Adcetris), ipilimumab (Yervoy), and nivolumab (Opdivo) in patients with relapsed/refractory Hodgkin lymphoma (HL). The data showed that the treatment combinations had promising effectiveness and manageable side effects. Some background...

Read More

Long-term outcomes of idelalisib treatment for patients with relapsed painless lymphoma

Long-term outcomes of idelalisib treatment for patients with relapsed painless lymphoma

Posted by on Jan 31, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety outcomes of treatment with idelalisib (Zydelig) after a longer follow-up of patients with indolent (painless) non-Hodgkin lymphoma. The data showed that idelalisib treatment improved the overall survival of these patients in the long-term. Some background Non-Hodgkin...

Read More

Testing the safety and effectiveness of loncastuximab tesirine for the treatment of relapsed/refractory B-cell non-hodgkin lymphoma

Testing the safety and effectiveness of loncastuximab tesirine for the treatment of relapsed/refractory B-cell non-hodgkin lymphoma

Posted by on Dec 26, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to evaluate the safety and effectiveness of loncastuximab tesirine (LoT; Lonca) for the treatment of patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The study found that LoT was safe and had promising activity in these patients.  Some background B-NHL is a type of...

Read More

Searching for patients with metastatic breast cancer to trial a targeted therapy

Searching for patients with metastatic breast cancer to trial a targeted therapy

Posted by on Dec 15, 2020 in Breast cancer | 0 comments

In a nutshell This phase 2 clinical trial is evaluating the safety and effectiveness of targeted therapy TAS-120 (futibatinib) alone or in combination with fulvestrant (Faslodex) in patients with metastatic breast cancer (mBC). The main outcomes to be evaluated will be the response rate and survival without cancer worsening. The details Breast...

Read More

Pomalidomide, bortezomib and dexamethasone for multiple myeloma relapsed after lenalidomide treatment

Pomalidomide, bortezomib and dexamethasone for multiple myeloma relapsed after lenalidomide treatment

Posted by on Dec 13, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the outcomes for patients with multiple myeloma (MM) who were treated with pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (Decadron) after relapsing following lenalidomide (Revlimid) treatment.  This study concluded that this treatment combination was effective in...

Read More

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Posted by on Nov 22, 2020 in Breast cancer | 0 comments

In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...

Read More

Searching for patients with advanced lung cancer to trial a new immune treatment.

Searching for patients with advanced lung cancer to trial a new immune treatment.

Posted by on Nov 8, 2020 in Lung cancer | 0 comments

In a nutshell This trial is looking at the effectiveness, safety, and tolerability of ladiratuzumab vedotin (LV) in patients with advanced solid tumors, including lung cancer. The main outcome to be measured in this trial is the response rate to the new drug. The details Advanced tumors have spread from the organ where they originated. These tumors...

Read More

Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Posted by on Nov 2, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the combination of zanubrutinib (Brukinsa) and obinutuzumab (Gazyva) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL). This study concluded that this combination was well tolerated and had promising responses in these patients.  Some...

Read More

Evaluating the impact of novel agents on allogeneic stem cell transplant outcomes for chronic lymphocytic leukemia 

Evaluating the impact of novel agents on allogeneic stem cell transplant outcomes for chronic lymphocytic leukemia 

Posted by on Oct 17, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if allogeneic stem cell transplantation (allo-SCT) was a safe and effective option for the treatment of patients with chronic lymphocytic leukemia (CLL) after treatment with novel agents (NA).  This study concluded that this treatment option was safe and effective for patients with...

Read More

Cladribine, G-CSF, cytarabine and aclarubicin in patients with relapsed/refractory acute myeloid leukemia 

Cladribine, G-CSF, cytarabine and aclarubicin in patients with relapsed/refractory acute myeloid leukemia 

Posted by on Oct 17, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of C-CAG including cladribine (Leustatin), granulocyte colony-stimulating factor (G-CSF, Neupogen), cytarabine (Cytosar-U), and aclarubicin (Aclacinon) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML).   This study...

Read More